Log In
BCIQ
Print this Print this
 

namacizumab (RYI-018)

  Manage Alerts
Collapse Summary General Information
Company Bird Rock Bio Inc.
DescriptionAantibody targeting cannabinoid CB1 receptor (CNR1)
Molecular Target Cannabinoid CB1 receptor (CNR1)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/05/2017

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today